"We struggled - boy, did we struggle - with this decision"
June 12, 2017 10:53 AM Subscribe
In Tarceva, Genentech discovered that they had a perfectly-targeted drug: Only patients with specific mutations in their epidermal growth factor receptor gene responded to the cancer-controlling drug. But there was one big problem: They were already selling $150 million a year worth of the drug to cancer patients for whom it didn't work.
This thread has been archived and is closed to new comments